The pharmacogenomics of selective serotonin reuptake inhibitors

Pharmacogenomics Journal

Volumn 4, Issue 4, 2004, Pages 233-244

  Serretti, Alessandro ^a   Artioli, P ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Antidepressant response; Pharmacogenetics; SSRI

Indexed keywords

AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ANTIDEPRESSANT AGENT; BETA 1 ADRENERGIC RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE; DOPAMINE RECEPTOR; DRUG METABOLIZING ENZYME; FLUVOXAMINE; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 1BETA; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; N ETHYL 3,4 METHYLENEDIOXYAMPHETAMINE; NEUROLEPTIC AGENT; NITRIC OXIDE SYNTHASE; NORTRIPTYLINE; PAROXETINE; PINDOLOL; PROTEIN SUBUNIT; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN HYDROXYLASE; UNINDEXED DRUG;

BIPOLAR DEPRESSION; CLINICAL TRIAL; DEPRESSION; DNA MICROARRAY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RESPONSE; DRUG TOLERABILITY; GENE IDENTIFICATION; GENE MAPPING; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MAJOR DEPRESSION; MEDICAL DECISION MAKING; MENTAL DISEASE; NAUSEA; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; REMISSION; REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOMATOLOGY; TREATMENT PLANNING;

ANTIDEPRESSIVE AGENTS; HUMANS; MENTAL DISORDERS; MONOAMINE OXIDASE; PHARMACOGENETICS; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TRYPTOPHAN HYDROXYLASE;

EID: 4344700605     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500250     Document Type: Review

References (124)

1. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: treatment of bipolar depression. World J Biol Psychiatry 2002; 3: 115-124.
2. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J. SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev 2000; 2: CD001851.
3. Orsini A. Antidepressant responses and segregation analyses in affective families. In: Racagni G, Smeraldi E (eds). Anxious Depression: Assessment and Treatment. Raven Press: New York 1987.
4. Sederer LI. Depression. In: Sederer LI (ed). Inpatients Psychiatry Diagnosis and Treatment. William & Wilkins: Baltimore, MD 1986; pp 20.
5. Berrettini W. Progress and pitfalls: bipolar molecular linkage studies. J Affect Disorders 1998; 50: 287-297.
6. Pare CM, Mack JW. Differentiation of two genetically specific types of depression by the response to antidepressant drugs. J Med Genet 1971; 8: 306-309.
7. Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet 1999; 56: 247-258.
8. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association. Am J Psychiatry 1994; 151: 1-36.
9. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. Am J Psychiatry 1997; 154: 1-63.
10. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000; 157: 1-45.
11. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405: 857-865.
12. Dettling M, Cascorbi I, Roots I, Mueller-Oerlinghausen B. Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish Caucasian sample. Arch Gen Psychiatry 2001; 58: 93-94.
13. Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999; 4: 247-253.
14. Pickar D, Rubinow K. Pharmacogenomics of psychiatric disorders. Trends Pharmacol Sci 2001; 22: 75-83.
15. Stahl SM, Grady MM. Differences in mechanism of action between current and future antidepressants. J Clin Psychiatry 2003; 64(Suppl 13): 13-17.
16. Serretti A, Lilli R, Smerladi E. Pharmacogenetics in affective disorders. Eur J Pharmacol 2002; 438: 117-128.
17. Boularand S, Darmon MC, Ganem Y, Launay JM, Mallet J. Complete coding sequence of human tryptophan hydroxylase. Nucleic Acid Res 1990; 18: 4257.
18. Craig SP, Boularand S, Darmon MC, Mallet J, Craig IW. Localization of human tryptophan hydroxylase (TPH) to chromosome 11p15.3-p14 by in situ hybridization. Cytogenet Cell Genet 1991; 56: 157-159.
19. Johnson M, Hanson GR, Gibb JW. Characterization of acute N-ethyl-3,4-methylenedioxyamphetamine (MDE) action on the central serotonergic system. Biochem Pharmacol 1989; 38: 4333-4338.
20. Kim SW, Park SY, Hwang O. Up-regulation of tryptophan hydroxylase expression and serotonin synthesis by sertraline. Mol Pharmacol 2002; 61: 778-785.
21. Nielsen DA, Jenkins GL, Stefanisko KM, Jefferson KK, Goldman D. Sequence, splice site and population frequency distribution analyses of the polymorphic human tryptophan hydroxylase intron 7. Mol Brain Res 1997; 45: 145-148.
22. Jonsson EG, Goldman D, Spurlock G, Gustavsson JP, Nielsen DA, Linnoila M et al. Tryptophan hydroxylase and catechol-O-methyl-transferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Eur Arch Psychiatry Clin Neurosci 1997; 247: 297-302.
23. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001; 6: 586-592.
24. Serretti A, Zanardi R, Cusin C, Rossini D, Lorenzi C, Smeraldi E. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol 2001; 11: 375-380.
25. Yoshida K, Naito S, Takahashi H, Sato K, Ito K, Kamata M et al. Monoamine oxidase: a gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1279-1283.
26. Takahashi H, Yoshida K, Ito K, Sato K, Kamata M, Higuchi H et al. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. Eur Neuropsychopharmacol 2002; 12: 477.
27. Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003; 299: 76.
28. Walther DJ, Bader M. A unique central tryptophan hydroxylase isoform. Biochem Pharmacol 2003; 66: 1673-1680.
29. Berry MD, Juorio AV, Paterson IA. The functional role of monoamine oxidases A and B in the mammalian central nervous system. Prog Neurobiol 1994; 42: 375-391.
30. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 1998; 103: 273-279.
31. Denney RM, Koch H, Craig IW. Association between monoamine oxidase A activity in human male skin fibroblasts and genotype of the MAOA promoter-associated variable number tandem repeat. Hum Genet 1999; 105: 542-551.
32. Muller DJ, Schulze TG, Macciardi F, Ohlraun S, Gross MM, Bauer I et al. Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase-A promoter. Eighth World Congress on Psychiatric Genetics , 2000, Versailles, France, p. 537.
33. Cusin C, Serretti A, Zanardi R, Lattuada E, Rossini D, Lilli R et al. Influence of monoamine oxydase A and serotonin receptor 2A polymorphisms in SSRIs antidepressant activity. Int J Neuropsychopharmacol 2002; 5: 27-35.
34. Kirigiti P, Yang YF, Li X, Li B, Midson CN, Machida CA. Rat beta 1-adrenergic receptor regulatory region containing consensus AP-2 elements recognizes novel transactivator proteins. Mol Cell Biol Res Commun 2000; 3: 181-192.
35. Crissman AM, Makhay MM, O'Donnell JM. Discriminative stimulus effects of centrally administered isoproterenol in rats: mediation by beta-1 adrenergic receptors. Psychopharmacology (Berl) 2001; 154: 70-75.
36. Yang-Feng TL, Xue FY, Zhong WW, Cotecchia S, Frielle T, Caron MG et al. Chromosomal organization of adrenergic receptor genes. Proc Natl Acad Sci USA 1990; 87: 1516-1520.
37. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999; 274: 12670-12674.
38. D'Aquila PS, Collu M, Gessa GL, Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000; 405: 365-373.
39. Civelli O. Molecular biology of the dopamine receptor subtypes. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven press: New York 1995; pp 155-161.
40. Dong J, Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl) 2001; 155: 52-57.
41. Grandy D, Litt M, Allen L, Bunzow J, Marchionni M, Makam H et al. The human D2 dopamine receptor gene is located on chromosome 11 at q22-q23 and identifies a Taql RFLP. Am J Hum Genet 1989; 45: 778-785.
42. Balk J, Picetti R, Salardi A, Thirlet G, Dierich A, Depaulls A et al. Parkinsonian-like locomotorimpairment in mice lacking dopamine D2 receptors. Nature 1995; 377: 424-428.
43. Itokawa M, Arinami T, Futamura N, Hamaguchi H, Toru M. A structural polymorphism of human dopamine D2 receptor, D2(Ser311→ Cys). Biochem Biophys Res Commun 1993; 196: 1369-1375.
44. Rubinstein M, Phillips TJ, Bunzow JR, Falzone TL, Dziewczapolski G, Zhang G et al. Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell 1997; 90: 991-1001.
45. Price CJ, Pittman QJ. Dopamine D4 receptor activation inhibits presynaptically glutamatergic neurotransmission in the rat supraoptic nucleus. J Neurophysiol 2001; 86: 1149-1155.
46. Van Tol H, Caren M, Guan H, Ohara K, Bunzow J, Civelli O et al. Multiple dopamine D4 receptor variants in the human population. Nature 1992; 358: 149-152.
47. Serretti A, Zanardi R, Cusin C, Rossini D, Lilli R, Lorenzi C et al. No association between dopamine D2 and D4 receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. Psychiatry Res 2001; 104: 195-203.
48. Sparkes RS, Lan N, Klisak I, Mohandas T, Diep A, Kojis T et al. Assignment of a serotonin 5HT-2 receptor gene (HTR2) to human chromosome 13q14-q21 and mouse chromosome 14. Genomics 1991; 9: 461-465.
49. Skrebuhhova T, Allikmets L, Matto V. Effects of anxiogenic drugs in rat forced swimming test. Methods Find Exp Clin Pharmacol 1999; 21: 173-178.
50. Hemrick-Luecke SK, Snoddy HD, Fuller RW. Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci 1994; 55: 479-483.
51. Spurlock G, Heils A, Holmans P, Williams J, D'Souza UM, Cardno A et al. A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry 1998; 3: 42-49.
52. Arranz MJ, Munro J, Owen MJ, Spurlock G, Sham PC, Zhao J et al. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry 1998; 3: 61-66.
53. Warren Jr JT, Peacock ML, Rodriguez LC, Fink JK. An Mspl polymorphism in the hyman serotonin receptor gene (HTR2): detection by DGGE and RFLP analysis. Hum Mol Genet 1993; 2: 338.
54. Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry 2002; 159: 1593-1595.
55. Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995; 346: 281-282.
56. Sato K, Yoshida K, Takahashi H, Ito K, Kamata M, Higuchi H et al. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 2002; 46: 136-140.
57. Minov C, Baghai TC, Schule C, Zwanzger P, Schwarz MJ, Zill P et al. Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett 2001; 303: 119-122.
58. Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE et al. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem 1996; 66: 47-56.
59. Wu WH, Huo SJ, Cheng CY, Hong CJ, Tsai SJ. Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology 2001; 44: 172-175.
60. Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS et al. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA 1993; 90: 2542-2546.
61. Lesch KP, Balling U, Gross J, Strauss K, Wolozin BL, Murphy DL et al. Organization of the human serotonin transporter gene. J Neural Transm Gen Sect 1994; 95: 157-162.
62. Ogilvie AD, Battersby S, Bubb VJ, Fink G, Harmar AJ, Goodwin GM et al. Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 1996; 347: 731-733.
63. Heils A, Teufel A, Petri S, Stöber G, Riederer P, Bengel D et al. Allelic variation of human serotonin trasporter gene expression. J Neurochem 1996; 66: 2621-2624.
64. Lesch K, Bengel D, Heils A, Sabol S, Greenberg B, Petri S et al. Association of anxiety-related traits with a polymorphismin the serotonin transporter gene regulatory region. Science 1996; 274: 1527-1530.
65. Smeraldi E, Zanardi R, Benedetti F, Dibella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3: 508-511.
66. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 2001; 50: 323-330.
67. Zanardi R, Benedetti F, DiBella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene. J Clin Psychopharmacol 2000; 20: 105-107.
68. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587-590.
69. Arias B, Catalan R, Gasto C, Imaz ML, Gutierrez B, Pintor L et al. Genetic variability in the promoter region of the serotonin transporter gene is associated with clinical remission of major depression after long term treatment with citalopram. World Federation of Societies of Biological Psychiatry, 2001, Berlin, Germany, p. 9S.
70. Rausch JL, Johnson ME, Fei Y-J, Li JQ, Shendarkar N, Mac Hobby H et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 2002; 51: 723-732.
71. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11: 215-219.
72. Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 383-386.
73. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002; 7: 1115-1119.
74. Ito K, Yoshida K, Sato K, Takahashi H, Kamata M, Higuchi H et al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res 2002; 111: 235-239.
75. Mundo E, Walker M, Cate T, Macciardi F, Kennedy JL. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder. Arch Gen Psychiatry 2001; 58: 539-544.
76. Artioli P, Serretti A, Lattuada E, Lorenzi C, Lilli R, Smeraldi E. Clinical and genetic features of antidepressant induced mania in bipolar disorder. Xth World Congress of Psychiatric Genetics , 2002, Brussels, p. 755.
77. Wegener G, Volke V, Harvey BH, Rosenberg R. Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res 2003; 959: 128-134.
78. Nowak G, Kata M, Jopek R, Siedlecki A. Chronic electroconvulsive treatment increases the activity of nitric oxide synthase in the rat brain. Pol J Pharmacol 1997; 49: 379-382.
79. Paul IA. Antidepressant activity and calcium signaling cascades. Hum Psychopharmacol 2001; 16: 71-80.
80. Yu YW, Chen TJ, Wang YC, Liou YJ, Hong CJ, Tsai SJ. Association analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluoxetine response. Neuropsychobiology 2003; 47: 137-140.
81. Neer EJ. Heterotrimeric G proteins: organizers of transmembrane signals. Cell 1995; 80: 249-257.
82. Elena Castro M, Diaz A, del Olmo E, Pazos A. Chronic fluoxetine induces opposite changes in G protein coupling at pre and post-synaptic 5-HT(1A) receptors in rat brain. Neuropharmacology 2003; 44: 93-101.
83. Siffert W, Rosskopf D, Moritz A, Wieland T, Kaldenberg-Stasch S, Kettler N et al. Enhanced G protein activation in immortalized lymphoblasts from patients with essential hypertension. J Clin Invest 1995; 96: 759-766.
84. Zill P, Baghai TC, Zwanzger P, Schule C, Minov C, Riedel M et al. Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport 2000; 11: 1893-1897.
85. Serretti A, Lorenzi C, Cusin C, Zanardi R, Lattuada E, Rossini D et al. SSRIs antidepressant activity is influenced by Gbeta3 variants. Eur Neuropsychopharmacol 2003; 13: 117-122.
86. Ramaraj P, Kessler SP, Colmenares C, Sen GC. Selective restoration of male fertility in mice lacking angiotensin-converting enzymes by sperm-specific expression of the testicular isozyme. J Clin Invest 1998; 102: 371-378.
87. Ehlers MR, Fox EA, Strydom DJ, Riordan JF. Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme. Proc Natl Acad Sci USA 1989; 86: 7741-7745.
88. Jeunemaitre X, Rigat B, Charru A, Houot AM, Soubrier F, Corvol P. Sib pair linkage analysis of renin gene haplotypes in human essential hypertension. Hum Genet 1992; 88: 301-306.
89. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
90. Jeffery S, Saggar Malik AK, Crosby A, Bland M, Eastwood JB, Amoah-Danquah J et al. A dominant relationship between the ACE D allele and serum ACE levels in a Ghanaian population. J Med Genet 1999; 36: 869-870.
91. Vuckovic A, Cohen BM, Zubenko GS. The use of captopril in treatment-resistant depression: an open trial. J Clin Psychopharmacol 1991; 11: 395-396.
92. Arregui A, MacKay AV, Iversen LL, Spokes EG. Reduction of angiotensin-converting enzyme in substantia nigra in early-onset schizophrenia. N Engl J Med 1979; 300: 502-503.
93. Arinami T, Li L, Mitsushio H, Itokawa M, Hamaguchi H, Toru M. An insertion/deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders. Biol Psychiatry 1996; 40: 1122-1127.
94. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640-1645.
95. Baghai TC, Schule C, Zwanzger P, Minov C, Schwarz MJ, de Jonge S et al. Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders. Mol Psychiatry 2001; 6: 258-259.
96. Hong CJ, Wang YC, Tsai SJ. Association study of angiotensin I-converting enzyme polymorphism and symptomatology and antidepressant response in major depressive disorders. J Neural Transm 2002; 109: 1209-1214.
97. Patterson D, Jones C, Hart I, Bleskan J, Berger R, Geyer D et al. The human interleukin-1 receptor antagonist (IL1 RN) gene is located in the chromosome 2q14 region. Genomics 1993; 15: 173-176.
98. Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci USA 1984; 81: 7907-7911.
99. Auron PE, Rosenwasser LJ, Matsushima K, Copeland T, Dinarello CA, Oppenheim JJ et al. Human and murine interleukin 1 possess sequence and structural similarities. J Mol Cell Immunol 1985; 2: 169-177.
100. Le Beau MM, Rowley JD. Chromosomal abnormalities in leukemia and lymphoma: clinical and biological significance. Adv Hum Genet 1986; 15: 1-54.
101. Owen B, Eccleston D, Ferrier I, Young A. Raised levels of plasma interleukin-1 in major and post viral depression. Acta Psychiatr Scand 2000; 103: 226-228.
102. Maes M, Bosmans E, Meltzer HY, Scharpe S, Suy E. Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 1993; 150: 1189-1193.
103. Anisman H, Ravindran AV, Griffiths J, Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry 1999; 4: 182-188.
104. Anisman H, Kokkinidis L, Merali Z. Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes. Brain Behav Immun 2002; 16: 544-556.
105. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999; 461: 25-46.
106. Maier SF, Goehler LE, Fleshner M, Watkins LR. The role of the vagus nerve in cytokine-to-brain communication. Ann NY Acad Sci 1998; 840: 289-300.
107. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999; 4: 317-327.
108. Di Giovine F, Takhsh E, Blakemore A. Single base polymorphism at -511 in the human interleukin-1 gene (IL1). Hum Mol Genet 1992; 1: 450.
109. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A Taql polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992; 22: 396-402.
110. Guasch JF, Bertina RM, Reitsma PH. Five novel intragenic dimorphisms in the human interleukin-1 genes combine to high informativity. Cytokine 1996; 8: 598-602.
111. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402.
112. Yu YW, Chen TJ, Hong CJ, Chen HM, Tsai SJ. Association Study of the interleukin-1beta (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. Neuropsychopharmacology 2003; 28: 1182-1185.
113. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35: 361-390.
114. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002; 3: 13-37.
115. Smith G, Stubbins MJ, Harries LW, Wolf CR. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 1998; 28: 1129-1165.
116. Smith DA, Abel SM, Hyland R, Jones BC. Human cytochrome P450s: selectivity and measurement in vivo. Xenobiotica 1998; 28: 1095-1128.
117. Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 2002; 22: 1001-1006.
118. Liston HL, DeVane CL, Boulton DW, Risch SC, Markowitz JS, Goldman J. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol 2002; 22: 169-173.
119. de Leon J, Barnhill J, Rogers T, Boyle J, Chou WH, Wedlund PJ. Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. Am J Psychiatry 1998; 155: 1278-1280.
120. Steimer W, Muller B, Leucht S, Kissling W. Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta 2001; 308: 33-41.
121. Mancama D, Kerwin RW. Role of pharmacogenomics in individualising treatment with SSRIs. CNS Drugs 2003; 17: 143-151.
122. Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 1997; 51: 395-398.
123. Murphy Jr GM, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160: 1830-1835.
124. Zill P, Baghai TC, Engel R, Zwanzger P, Schule C, Minov C et al. Beta-1-adrenergic receptor gene in major depression: Influence on antidepressant treatment response. Am J Med Genet 2003; 120B: 85-89.